EMA gives trastuzumab biosimilar Marketing Authorisation Application

29th May 2019 Uncategorised 0

The drug is Prestige’s lead development candidate biosimilar to Roche’s Herceptin.

More: EMA gives trastuzumab biosimilar Marketing Authorisation Application
Source: News